Findings
hypoxic ischemic encephalopathy
SECONDARY, HYPOXIC ISCHEMIC ENCEPHALOPATHY
In this secondary analysis of a randomized clinical trial of 180 neonates with hypoxic ischemic encephalopathy and complete biomarker and outcome data, erythropoietin treatment did not affect the measured circulating biomarker concentrations. A combination of inflammatory mediators and brain-specific proteins drawn at baseline, day 2, and day 4 significantly improved accuracy for estimation of neurodevelopmental outcomes vs that obtained with clinical data alone.